

#### **Akamai Cannabis Clinic**

3615 Harding Ave, Suite 304 Honolulu, HI 96816

# TESTIMONY ON SENATE BILL 1266 RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT By Clifton Otto, MD

Senate Committee on Commerce, Consumer Protection, and Health Senator Rosalyn H. Baker, Chair Senator Stanley Chang, Vice Chair

Wednesday, February 13, 2019; 9:10 AM State Capitol, Conference Room 229

Thank you for the opportunity to provide testimony on this measure. Please consider the following comments related to this bill:

1 - If the reason for annually updating Hawaii's Uniform Controlled Substances Act is to harmonize the state and federal regulation of controlled substances, then the Drug Enforcement Administration (DEA) Marijuana Extract rule needs to be considered:

https://www.federalregister.gov/documents/2016/12/14/2016-29941/establishment-of-anew-drug-code-for-marihuana-extract

21 CFR 1308.11(d) (58) Marihuana Extract - 7350

"Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant."

https://www.deadiversion.usdoj.gov/schedules/marijuana/m\_extract\_7350.html

2 - A controlled substance with accepted medical use cannot have the highest degree of danger. The following amendment needs to be made to Hawaii's Uniform Controlled Substances Act in order to harmonize the accepted medical use of cannabis in Hawaii with state scheduling regulations:

Testimony on SB1266 Senate Committee on Commerce, Consumer Protection, and Health February 13, 2019 Page 2

Section 329-14, Hawaii Revised Statutes, is amended by adding the following subsection:

- (f) The enumeration of cannabis, tetrahydrocannabinols or chemical derivatives of these as Schedule I controlled substances does not apply to the medical use of cannabis pursuant to Section 329, Part IX, and Section 329D, Hawaii Revised Statutes.
- 3 If FDA-approved Cannabidiol (CBD) needs to be placed into a state controlled substance schedule that is similar to the federal schedule adopted by the DEA, then what does this tell us about the current scheduling of non-FDA-approved CBD? Hawaii is being inundated with imported and locally formulated CBD products without any regulation to insure consumer safety or compliance with state and federal controlled substance regulation. Before allowing this bill to pass through your committee, please address the scheduling status of non-FDA-approved CBD by answering the following question:

Is CBD a tetrahydrocannabinol or a derivative of a tetrahydrocannabinol?

HRS 329-14. Schedule I. (a) The controlled substances listed in this section are included in Schedule I.

- (g) Any of the following cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
- (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, **derivatives**, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers (since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions, are covered);

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154432/pdf/can.2018.0030.pdf

Delta-8-THC (Delta-6-THC):

https://pubchem.ncbi.nlm.nih.gov/compound/2977#section=Top

Delta-9 THC (Delta-1-THC):

https://pubchem.ncbi.nlm.nih.gov/compound/Dronabinol#section=Top

Testimony on SB1266 Senate Committee on Commerce, Consumer Protection, and Health February 13, 2019 Page 3

#### 8 JOURNAL OF CANNABIS THERAPEUTICS

TABLE 1. Cannabinoids of the  $\Delta^9$ -trans-tetrahydrocannabinol Type (Turner et al. 1980)

Cannabinoid	Abbreviation	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
Δ <sup>9</sup> -trans-tetrahydrocannabinolic acid A	Δ9-THCA	COOH	C <sub>5</sub> H <sub>11</sub>	Н
Δ9-trans-tetrahydrocannabinolic acid B	Δ <sup>9</sup> -THCA	Н	C <sub>5</sub> H <sub>11</sub>	COOH
Δ <sup>9</sup> -trans-tetrahydrocannabinol	Δ <sup>9</sup> -THC	Н	C <sub>5</sub> H <sub>11</sub>	Н
Δ9-trans-tetrahydrocannabinolic acid-C <sub>4</sub>		COOH or H	C <sub>4</sub> H <sub>9</sub>	H or COOH
Δ9-trans-tetrahydrocannabinol-C <sub>4</sub>	$\Delta^9$ -THC-C <sub>4</sub>	н	C <sub>4</sub> H <sub>9</sub>	н
Δ9-trans-tetrahydrocannabivarinic acid		COOH	C <sub>3</sub> H <sub>7</sub>	Н
Δ9-trans-tetrahydrocannabivarin	Δ9-THCV	н	C <sub>3</sub> H <sub>7</sub>	Н
Δ9-trans-tetrahydrocannabiorcolic acid		COOH or H	CH <sub>3</sub>	H or COOH
Δ9-trans-tetrahydrocannabiorcol	Δ9-THC-C₁	н	CH <sub>3</sub>	н

FIGURE 3. Cannabinoids of the  $\Delta^9$ -THC type. The most widespread cannabinoids are the phenolic  $\Delta^9$ -THC with 21 carbon atoms and a C<sub>5</sub> side chain (R<sub>2</sub> = C<sub>5</sub>H<sub>11</sub>) and its two corresponding carboxylic acids A and B (see Table 1).

## https://cannabis-med.org/data/pdf/2003-01-1.pdf

4 – The inter-island transportation of cannabis for personal medical use continues to be an issue that is requiring significant amounts of local law enforcement time due to the processing of patients at our state airports who have been referred by TSA, which is threatening the safety of our airports. Local law enforcement officers are also telling patients that they cannot travel with their medicine because it is against federal law, which is beyond the authority of a state law enforcement agency, and not entirely true because of the federal aviation regulation that specifically exempts the carriage of cannabis aboard aircraft if authorized by state law or state agency.

Testimony on SB1266 Senate Committee on Commerce, Consumer Protection, and Health February 13, 2019 Page 4

Therefore, in order to clarify the existing provisions for inter-island transport within Hawaii's Medical Use of Cannabis Act and to protect the right of patients to transport legal amounts of cannabis for personal medical use to other islands under state law and the Americans with Disabilities Act, the following amendment needs to be made to the Medical Use of Cannabis section of Hawaii's Uniform Controlled Substances Act:

### HRS 329-122(f):

"For purposes of interisland transportation, "transport" of cannabis, usable cannabis, or any manufactured cannabis product, by any means is allowable only by a qualifying patient or qualifying out-of-state patient for their personal medical use, or between a production center or retail dispensing location and a certified laboratory for the sole purpose of laboratory testing pursuant to section 329D-8, as permitted under section 329D-6(m) and subject to section 329D-6(j), and with the understanding that state law and its protections do not apply outside of the jurisdictional limits of the State. The Department of Transportation and the Department of Public Safety shall adopt rules to provide compliance with this section.

# 14 CFR 91.19 Carriage of narcotic drugs, marihuana, and depressant or stimulant drugs or substances.

- (a) Except as provided in paragraph (b) of this section, no person may operate a civil aircraft within the United States with knowledge that narcotic drugs, marihuana, and depressant or stimulant drugs or substances as defined in Federal or State statutes are carried in the aircraft.
- (b) Paragraph (a) of this section **does not apply** to any carriage of narcotic drugs, marihuana, and depressant or stimulant drugs or substances **authorized by** or under any Federal or **State statute** or by any Federal or **State agency**.